Image Place holder

Jhanelle Gray, MD


Specialty: Medical Oncology
Program: Thoracic Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

or call 1-888-MOFFITT
(1-888-663-3488)

Overview

Jhanelle E. Gray, MD, is a Medical Oncologist and the Director of Clinical Research in the Department of Thoracic Oncology at H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida. She received her undergraduate degree from the University of Florida and her medical degree from Cornell University Medical College in New York City. Following her internship and residency in Internal Medicine at Cornell, Dr. Gray returned to Florida and completed her Medical Oncology Fellowship at Moffitt. She is a faculty member in the Department of Thoracic Oncology at Moffitt Cancer Center where she has been practicing since 2007. Dr. Gray believes in empowering patients by providing the necessary information and recommendations that will help them make the right decisions to meet their needs. She is continually impressed by her patients’ courage in the face of adversity and is motivates to make a difference in their lives. Although Dr. Gray focuses her clinical attentions on lung cancer, she is also deeply involved in clinical research. She is the lead investigator on many thoracic clinical trials especially research investigating novel drug combinations and personalized treatment to advance the fight against lung cancer. As the Director for Clinical Research in the Department of Thoracic Oncology, Dr. Gray directly supervises and manages the thoracic clinical research team as well as the structuring and development of our clinical trial portfolio. In this role, she fosters the clinical trial development through intra- and extramural collaborations between our medical, surgical, and radiation oncologists, research scientists, pathologists, and epidemiologists in the Department of Thoracic Oncology.  Moffitt’s emphasis on translational research benefits patients by turning basic science research in the lab into new clinical advances that improve outcomes and quality of life. In addition, Dr. Gray reports that Moffitt is making great strides toward understanding the molecular and genetic factors that will allow each patient to have a personalized care plan.

Education & Training

Board Certification:

  • Hematology
  • Medical Oncology

Fellowship:

  • H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL - Hematology/Oncology

Residency:

  • The New York Presbyterian Hospital, New York, NY -

Medical School:

  • Weill Medical College of Cornell University, New York, NY - MD
Participating Trials

CLINICAL TRIAL 18558
A Phase 1B/2 Open-Label Study to Evaluate Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of Avelumab (MSB00100718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies
Condition: Thoracic
Intervention: Avelumab; MSB00100718C (Avelumab); PD 0360324; PF-04518600; PF-05082566 (utomilumab)
Open

CLINICAL TRIAL 17971
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Condition: Thoracic
Intervention: Not Applicable
Open

CLINICAL TRIAL 18197
A Phase 2 Study of MM-121 in Combination with Docetaxel or Pemetrexed versus Docetaxel or Pemetrexed Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: Alimta (Pemetrexed); MM-121; Not Applicable; Pemetrexed; Taxotere (docetaxel); docetaxel
Open

CLINICAL TRIAL 18398
Novartis Pharmaceuticals trial entitled: A phase II, multicenter, study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC)
Condition: Thoracic
Intervention: INC280 (Capmatinib)
Open

CLINICAL TRIAL 18304
A Phase II Trial of AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer
Condition: Thoracic
Intervention: AZD1775; MK-1775 (AZD1775); Paraplatin (carboplatin); Taxol (paclitaxel); carboplatin; paclitaxel
Open

CLINICAL TRIAL 17908
Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer (Screening Step)
Condition: Thoracic
Intervention: 750009 (Rilotumumab); 765338 (AZD4547); 772256 (Palbociclib); AMG102 (Rilotumumab); AZD4547; BMN-673 (Talazoparib); BMS-936558 (Nivolumab); Dexamethasone; Erlotinib; GDC-0032 (Taselisib); Ipilimumab; MEDI4736 (Durvalumab); Nivolumab; Palbociclib; Rilotumumab; Talazoparib; Tarceva (Erlotinib); Taxotere (docetaxel); Yervoy (Ipilimumab); docetaxel
Open

CLINICAL TRIAL 17970
A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Condition: Thoracic
Intervention: Crizotinib; Not Applicable; Placebo; Xalkori (Crizotinib)
Open

CLINICAL TRIAL 17969
Randomized Study of Erlotinib vs. Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Condition: Thoracic
Intervention: Erlotinib; Not Applicable; Placebo; Tarceva (Erlotinib)
Open

CLINICAL TRIAL 17361
A Phase I/IB Trial of MEK162 in Combination with Erlotinib in NSCLC Harboring KRAS or EGFR Mutation
Condition: Thoracic
Intervention: Erlotinib; MEK162; Tarceva (Erlotinib)
Open

CLINICAL TRIAL 18494
A Phase I/II Study of Pembrolizumab and Vorinostat in Patients with Immune Therapy Naïve and Immune Therapy Pretreated Stage IV NSCLC
Condition: Thoracic
Intervention: Pembrolizumab (Keytruda); SAHA (Vorinostat); Vorinostat; Zolinza (Vorinostat); suberoylanilide hydroxamic acid (Vorinostat)
Open

CLINICAL TRIAL 18909
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Condition: Thoracic
Intervention: BMS-936558 (Nivolumab); Nivolumab; Not Applicable
Open

CLINICAL TRIAL 19083
A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: Atezolizumab (Tecentriq); Daratumumab
Open

CLINICAL TRIAL 19082
A Phase I/Ib Trial of Pirfenidone Combined with Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
Condition: Thoracic
Intervention: Alimta (Pemetrexed); Paraplatin (carboplatin); Pemetrexed; Pirfenidone; Taxol (paclitaxel); carboplatin; paclitaxel
Open

CLINICAL TRIAL 16480
Radiomics: A Prospective Study of Outcome in Lung Cancer
Condition: Thoracic
Intervention:
Open

CLINICAL TRIAL 18431
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Non-Small Cell Lung Cancer (NSCLC)
Condition: Thoracic
Intervention:
Open

CLINICAL TRIAL 18522
A Phase I Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE-A10c796T in Subjects with Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
Condition: Thoracic
Intervention: MAGE-A10c796T
Open

CLINICAL TRIAL 18515
Symptoms, Toxicity Prevalence and Quality of Life Benefit of Targeted Therapies and Immunotherapies in Lung Cancer Patients: An Observational Prospective Cohort Study within the Total Cancer Care Population
Condition: Thoracic
Intervention:
Open

CLINICAL TRIAL 18503
STARTRK-2: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Condition: Thoracic
Intervention: Entrectinib
Open

CLINICAL TRIAL 18342
A Pilot Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects with Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
Condition: Thoracic
Intervention: G-CSF; MESNA; NY-ESO-1c259T; cyclophosphamide; cytoxan (cyclophosphamide)
Open

CLINICAL TRIAL 18321
Phase I/Ib trial of single agent PBF-509 and in combination with PDR001 for patients with advanced NSCLC
Condition: Thoracic
Intervention: PBF-509; PDR001
Open

CLINICAL TRIAL 18517
A Randomized, Open-Label, Active-Controlled, Phase II Study of Intravenous Anetumab Ravtansine (BAY 94-9343) or Vinorelbine in Patients with Advanced or Metastatic Malignant Pleural Mesothelioma Overexpressing Mesothelin and Progressed on First Line Platinum/Pemetrexed-Based Chemotherapy
Condition: Thoracic
Intervention: Anetumab Ravtansine (BAY 94-9343); Navelbine (Vinorelbine); Vinorelbine
Open

CLINICAL TRIAL 18906
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Nivolumab; TSR-022; TSR-042
Open

CLINICAL TRIAL 18915
A Phase 1 Trial of MLN0128 (TAK-228) in Combination with Osimertinib (AZD9291) in Advanced EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) After Progression on a Previous EGFR Tyrosine Kinase Inhibitor
Condition: Thoracic
Intervention: AZD9291 (Osimertinib); MLN0128; Osimertinib; TAK-228 (MLN0128)
Open

CLINICAL TRIAL 17690
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients with Hepatic Dysfunction
Condition: Multiple
Intervention: GSK1120212 (Trametinib); Trametinib
Open

CLINICAL TRIAL 18835
Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial)
Condition: Thoracic
Intervention: Adriamycin (doxorubicin); PM01183 (lurbinectedin); Topotecan; Vincristine; cyclophosphamide; cytoxan (cyclophosphamide); doxorubicin
Open

CLINICAL TRIAL 18677
XALT3: Phase 3 Randomized Study Comparing X-396 to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Condition: Thoracic
Intervention: Crizotinib; X-396 (Ensartinib); Xalkori (Crizotinib)
Open

CLINICAL TRIAL 18904
Contributors to and Correlates of Loneliness in Lung Cancer Patients
Condition: Thoracic
Intervention:
Open

CLINICAL TRIAL 18393
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination with Pembrolizumab in Patients with B7-H3-Expressing Melanoma, Squamous Cell Cancer of the Head and Neck, or Squamous Cell Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: MGA271; Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 18685
Phase I/II, First-in-Human, Dose-Escalation Study of X-396 in Patients with Advanced Solid Tumors and Expansion Phase in Patients with ALK+ Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: X-396 (Ensartinib)
Open

CLINICAL TRIAL 18537
A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of a Novel Transforming Growth Factor-B Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination with Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumours (Phase 1b) and in Recurrent or Refractory Non-Small Cell Lung Cancer or Hepatocellular Carcinoma (Phase 2)
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Galunisertib; LY2157299 (Galunisertib); Nivolumab
Open

CLINICAL TRIAL 18871
A Phase II, Open-Label, Multicenter, Single-Arm Study to Investigate the Efficacy and Safety of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients with Stage IB, II, or IIIA Resectable and Untreated Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: Atezolizumab (Tecentriq)
Open

CLINICAL TRIAL 18537
A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of a Novel Transforming Growth Factor-B Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination with Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumours (Phase 1b) and in Recurrent or Refractory Non-Small Cell Lung Cancer or Hepatocellular Carcinoma (Phase 2)
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Galunisertib; LY2157299 (Galunisertib); Nivolumab
Open

CLINICAL TRIAL 18871
A Phase II, Open-Label, Multicenter, Single-Arm Study to Investigate the Efficacy and Safety of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients with Stage IB, II, or IIIA Resectable and Untreated Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: Atezolizumab (Tecentriq)
Open

CLINICAL TRIAL 18428
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)
Condition: Thoracic
Intervention: Crizotinib; Erlotinib; Paraplatin (carboplatin); Tarceva (Erlotinib); Taxol (paclitaxel); Xalkori (Crizotinib); carboplatin; cisplatin; etoposide; paclitaxel
Open

CLINICAL TRIAL 18561
A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158)
Condition: Multiple
Intervention: Not Applicable; Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 18938
A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*0401 Positive Subjects with Advanced Cancers
Condition: Multiple
Intervention: Aldesleukin (Interleukin-2); IL-2 (Interleukin-2); Interleukin-2; KITE-718; MESNA; Proleukin (Interleukin-2); cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 18928
A Phase III, Randomized, Open Label Trial of Nivolumab in combination with Ipilimumab versus Pemetrexed with Cisplatin or Carboplatin as First Line Therapy in unresectable Pleural Mesothelioma
Condition: Thoracic
Intervention: Alimta (Pemetrexed); BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Paraplatin (carboplatin); Pemetrexed; Yervoy (Ipilimumab); carboplatin; cisplatin
Open

CLINICAL TRIAL 18923
A Multi-Center Open-Label Phase 1/2 Study of BGB324 in Combination with Erlotinib in Patients with Stage IIIb or Stage IV Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: BGB324; Erlotinib; Tarceva (Erlotinib)
Open

CLINICAL TRIAL 19067
A Phase 2 Single-arm Study to Evaluate Safety and Efficacy of CRS-207 with Pembrolizumab in Adults with Previously-Treated Malignant Pleural Mesothelioma
Condition: Thoracic
Intervention: CRS-207; Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 18811
Randomized, Double-Blind, Phase 2/3 Study in Subjects with Malignant Pleural Mesothelioma with Low Argininosuccinate Synthetase 1 Expression to Assess ADI-PEG 20 with Pemetrexed and Cisplatin (ATOMIC-Meso Phase 2/3 Study)
Condition: Thoracic
Intervention: ADI-PEG 20; Alimta (Pemetrexed); Paraplatin (carboplatin); Pemetrexed; Placebo; carboplatin; cisplatin
Open

CLINICAL TRIAL 19101
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors
Condition: Thoracic
Intervention: BMS-936558 (Nivolumab); BMS-986205; Nivolumab
Open

CLINICAL TRIAL 18914
Consolidative Ipilimumab and Nivolumab with Thoracic Radiotherapy after Platinum Based Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer
Condition: Thoracic
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 19114
Phase 1/2 Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab Combined with Daratumumab in Participants with Advanced or Metastatic Solid Tumors
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Daratumumab; Nivolumab
Open

CLINICAL TRIAL 19122
A Phase I Clinical Trial Combining Nivolumab and Tumor Infiltrating Lymphocytes (TIL) for Patients with Advanced Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: Aldesleukin (Interleukin-2); BMS-936558 (Nivolumab); IL-2 (Interleukin-2); Interleukin-2; Nivolumab; Proleukin (Interleukin-2); TIL; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 19109
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-214 and Nivolumab in Patients with Select Locally Advanced or Metastatic Solid Tumor Malignancies
Condition: Genitourinary
Intervention: BMS-936558 (Nivolumab); NKTR-214; Nivolumab
Open

CLINICAL TRIAL 19320
An Open-Label, Multicenter Extension Study In Patients Previously Enrolled In A Genentech and/or F Hoffmann La Roche Ltd. Sponsored Atezolizumab Study
Condition: Thoracic
Intervention: Atezolizumab (Tecentriq)
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).

Publications

  • Meyer M, Vliegenthart R, Henzler T, Buergy D, Giordano FA, Kostrzewa M, Rathmann N, Brustugun OT, Crino L, Dingemans AC, Dusmet M, Fennell D, Grunenwald D, Huber RM, Moniuszko M, Mornex F, Papotti M, Pilz L, Senan S, Syrigos K, Pérol M, Gray JE, Schabel C, van Meerbeeck J, van Zandwijk N, Zhou CC, Manegold C, Voigt W, Roessner ED. Management of progressive pulmonary nodules found during and outside of CT lung cancer screening studies. J Thorac Oncol. 2017 Sep. Pubmedid: 28962947.
  • Hicks JK, Saller J, Wang E, Boyle T, Gray JE. Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results. Lung Cancer. 2017 Sep;111:135-138. Pubmedid: 28838384.
  • Gray JE, Heist RS, Starodub AN, Camidge DR, Kio EA, Masters GA, Purcell WT, Guarino MJ, Misleh J, Schneider CJ, Schneider BJ, Ocean A, Johnson T, Gandhi L, Kalinsky K, Scheff R, Messersmith WA, Govindan SV, Maliakal PP, Mudenda B, Wegener WA, Sharkey RM, Goldenberg DM. Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan. Clin Cancer Res. 2017 Oct;23(19):5711-5719. Pubmedid: 28679770.
  • Puri S, Chatwal M, Gray JE. Anti PD-L1 combined with other agents in non-small cell lung cancer: combinations with non-immuno-oncology agents. Expert Rev Respir Med. 2017 Oct;11(10):791-805. Pubmedid: 28786318.
  • Dagogo-Jack I, Saltos A, Shaw AT, Gray JE. Pathology Issues in Thoracic Oncology: Histologic Characterization and Tissue/Plasma Genotyping May Resolve Diagnostic Dilemmas. Am Soc Clin Oncol Educ Book. 2017 May;37:619-629. Pubmedid: 28561671.
  • Ahmed KA, Grass GD, Creelan B, Gray J, Kim S, Dilling TJ, Antonia SJ, Perez BA. Tolerability and Safety of Thoracic Radiation and Immune Checkpoint Inhibitors Among Patients with Lung Cancer. Int J Radiat Oncol Biol Phys. 2017 May;98(1):224. Pubmedid: 28586976.
  • Tanvetyanon T, Gray JE, Antonia SJ. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?. Expert Opin Biol Ther. 2017 Mar;17(3):305-312. Pubmedid: 28064556.
  • Ahmed KA, Kim S, Arrington J, Naghavi AO, Dilling TJ, Creelan BC, Antonia SJ, Caudell JJ, Harrison LB, Sahebjam S, Gray JE, Etame AB, Johnstone PA, Yu M, Perez BA. Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases. J Neurooncol. 2017 Jun;133(2):331-338. Pubmedid: 28466250.
  • Chen DT, Huang PY, Lin HY, Chiappori AA, Gabrilovich DI, Haura EB, Antonia SJ, Gray JE. A Bayesian pick-the-winner design in a randomized phase II clinical trial. Oncotarget. 2017 Jul. Pubmedid: 28706157.
  • Wright G, Golubeva V, Remsing Rix LL, Berndt N, Luo Y, Ward GA, Gray JE, Schönbrunn E, Lawrence HR, Monteiro ANA, Rix U. Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity. Acs Chem Biol. 2017 Jul;12(7):1883-1892. Pubmedid: 28557434. Pmcid: PMC5551971.
  • Manegold C, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT, Crino L, Felip E, Fennell D, Garrido P, Huber RM, Marabelle A, Moniuszko M, Mornex F, Novello S, Papotti M, Pérol M, Smit EF, Syrigos K, van Meerbeeck JP, van Zandwijk N, Chih-Hsin Yang J, Zhou C, Vokes E. The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. J Thorac Oncol. 2017 Feb;12(2):194-207. Pubmedid: 27729297.
  • Creelan BC, Gabrilovich DI, Gray JE, Williams CC, Tanvetyanon T, Haura EB, Weber JS, Gibney GT, Markowitz J, Proksch JW, Reisman SA, McKee MD, Chin MP, Meyer CJ, Antonia SJ. Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors. Onco Targets Ther. 2017 Aug;10:4239-4250. Pubmedid: 28919776. Pmcid: PMC5587199.
  • Simmons VN, Gray JE, Schabath MB, Wilson LE, Quinn GP. High-risk community and primary care providers knowledge about and barriers to low-dose computed topography lung cancer screening. Lung Cancer. 2017 Apr;106:42-49. Pubmedid: 28285693.
  • Simmons VN, Pineiro B, Hooper MW, Gray JE, Brandon TH. Tobacco-Related Health Disparities Across the Cancer Care Continuum. Cancer Control. 2016 Oct;23(4):434-441. Pubmedid: 27842333.
  • Portman DG, Thirlwell S, Donovan KA, Alvero C, Gray JE, Holloway R, Ellington L. Leveraging a Team Mental Model to Develop a Cancer Anorexia-Cachexia Syndrome Team. J Oncol Pract. 2016 Nov;12(11):1046-1052. Pubmedid: 27858539.
  • Schabath MB, Welsh EA, Fulp WJ, Chen L, Teer JK, Thompson ZJ, Engel BE, Xie M, Berglund AE, Creelan BC, Antonia SJ, Gray JE, Eschrich SA, Chen DT, Cress WD, Haura EB, Beg AA. Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma. Oncogene. 2016 Jun;35(24):3209-3216. Pubmedid: 26477306. Pmcid: PMC4837098.
  • Jhuraney A, Woods NT, Wright G, Rix L, Kinose F, Kroeger JL, Remily-Wood E, Cress WD, Koomen JM, Brantley SG, Gray JE, Haura EB, Rix U, Monteiro AN. PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer. Mol Cancer Ther. 2016 Jul;15(7):1669-1681. Pubmedid: 27196765. Pmcid: PMC4936941.
  • Chen L, Kurtyka CA, Welsh EA, Rivera JI, Engel BE, Muñoz-Antonia T, Yoder SJ, Eschrich SA, Creelan BC, Chiappori AA, Gray JE, Ramirez JL, Rosell R, Schabath MB, Haura EB, Chen DT, Cress WD. Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma. Oncotarget. 2016 Dec;7(50):82254-82265. Pubmedid: 27756884. Pmcid: PMC5347689.
  • Chen DT, Huang PY, Lin HY, Haura EB, Antonia SJ, Cress WD, Gray JE. Strategies for power calculations in predictive biomarker studies in survival data. Oncotarget. 2016 Dec;7(49):80373-80381. Pubmedid: 27661007. Pmcid: PMC5348326.
  • Beg AA, Gray JE. HDAC inhibitors with PD-1 blockade: a promising strategy for treatment of multiple cancer types?. Epigenomics. 2016 Aug;8(8):1015-1017. Pubmedid: 27410519.
  • Freeman-Keller M, Goldman J, Gray J. Vaccine immunotherapy in lung cancer: Clinical experience and future directions. Pharmacol Ther. 2015 Sep;153:1-9. Pubmedid: 25989231.
  • Vansteenkiste JF, Canon JL, De Braud F, Grossi F, De Pas T, Gray JE, Su WC, Felip E, Yoshioka H, Gridelli C, Dy GK, Thongprasert S, Reck M, Aimone P, Vidam GA, Roussou P, Wang YA, Di Tomaso E, Soria JC. Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study. J Thorac Oncol. 2015 Sep;10(9):1319-1327. Pubmedid: 26098748. Pmcid: PMC4646607.
  • Goldman JM, Gray JE. BRAF V600E mutations: a series of case reports in patients with non-small cell lung cancer. Cancer Genet. 2015 Jun;208(6):351-354. Pubmedid: 26066373.
  • Jacobsen PB, Lee JH, Fulp W, Siegel EM, Shibata D, Laronga C, Gray J, Tanvetyanon T, Schreiber F, Brown R, Levine R, Cartwright T, Abesada-Terk G, Kim G, Alemany C, Faig D, Sharp P, Markham MJ, Malafa M. Florida Initiative for Quality Cancer Care: Changes in Psychosocial Quality of Care Indicators Over a 3-Year Interval. J Oncol Pract. 2015 Jan;11(1):e103-e109. Pubmedid: 25352389. Pmcid: PMC4582141.
  • Tchekmedyian N, Gray JE, Creelan BC, Chiappori AA, Beg AA, Soliman H, Perez BA, Antonia SJ. Propelling Immunotherapy Combinations Into the Clinic. Oncology (Williston Park). 2015 Dec;29(12):990-1002. Pubmedid: 26680224.
  • Kumar NB, Quinn GP, Alexandrow MG, Gray J, Schell M, Sutton S, Haura EB. Chemoprevention Trial Feasibility Using Botanicals in Exceptionally High Risk Populations for Lung Cancer. J Clin Trials. 2014 Sep;4(4). Pubmedid: 26101725. Pmcid: PMC4474484.
  • Laronga C, Gray JE, Siegel EM, Lee JH, Fulp WJ, Fletcher M, Schreiber F, Brown R, Levine R, Cartwright T, Abesada-Terk G, Kim G, Alemany C, Faig D, Sharp P, Markham MJ, Shibata D, Malafa M, Jacobsen PB. Florida Initiative for Quality Cancer Care: improvements in breast cancer quality indicators during a 3-year interval. J Am Coll Surg. 2014 Oct;219(4):638-45.e1. Pubmedid: 25086813. Pmcid: PMC4505727.
  • Brana I, Berger R, Golan T, Haluska P, Edenfield J, Fiorica J, Stephenson J, Martin LP, Westin S, Hanjani P, Jones MB, Almhanna K, Wenham RM, Sullivan DM, Dalton WS, Gunchenko A, Cheng JD, Siu LL, Gray JE. A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. Brit J Cancer. 2014 Nov;111(10):1932-1944. Pubmedid: 25290091. Pmcid: PMC4229637.
  • Dilling TJ, Extermann M, Kim J, Thompson LM, Yue B, Stevens CW, Antonia S, Gray J, Williams C, Haura E, Pinder-Schenck M, Tanvetyanon T, Kim S, Chiappori A. Phase 2 study of concurrent cetuximab plus definitive thoracic radiation therapy followed by consolidation docetaxel plus cetuximab in poor prognosis or elderly patients with locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014 Nov;90(4):828-833. Pubmedid: 25216856.
  • Gray J, Haura EB, Chiappori A, Tanvetyanon T, Williams CC, Pinder-Schenk M, Kish JA, Kreahling JM, Lush RM, Neuger AM, Tetteh LF, Akar A, Zhao X, Schell MJ, Bepler G, Altiok S. A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors. Clin Cancer Res. 2014 Mar;20(6):1644-1655. Pubmedid: 24429877. Pmcid: PMC4051132.
  • O'Reilly M, Federoff HJ, Fong Y, Kohn DB, Patterson AP, Ahmed N, Aravind A, Boye SE, Crystal R, De Oliveira S, Gargiulo L, Harper SQ, Ikeda Y, Jambou R, Montgomery M, Prograis L, Rosenthal E, Sterman DH, Vandenberghe LH, Zoloth L, Abedi M, Adair J, Adusumilli PS, Goins WF, Gray J, Monahan P, Popplewell L, Sena-Esteves M, Tannous B, Weber T, Wierda W, Gopal-Srivastava R, McDonald CL, Rosenblum D, Corrigan-Curay J. Gene therapy: charting a future course--summary of a National Institutes of Health Workshop, April 12, 2013. Hum Gene Ther. 2014 Jun;25(6):488-497. Pubmedid: 24773122. Pmcid: PMC4064731.
  • Schabath MB, Thompson ZJ, Gray JE. Temporal trends in demographics and overall survival of non-small-cell lung cancer patients at Moffitt Cancer Center from 1986 to 2008. Cancer Control. 2014 Jan;21(1):51-56. Pubmedid: 24357741. Pmcid: PMC4341967.
  • Pratt Pozo CL, Morgan MA, Gray JE. Survivorship issues for patients with lung cancer. Cancer Control. 2014 Jan;21(1):40-50. Pubmedid: 24357740.
  • Gray J, Haura E. Update on third-generation EGFR tyrosine kinase inhibitors. Transl Lung Cancer Res. 2014 Dec;3(6):360-2. Pubmedid: 25806319. Pmcid: PMC4367680 .
  • Schabath MB, Giuliano AR, Thompson ZJ, Amankwah EK, Gray J, Fenstermacher DA, Jonathan KA, Beg AA, Haura EB. TNFRSF10B polymorphisms and haplotypes associated with increased risk of death in non-small cell lung cancer. Carcinogenesis. 2013 Nov;34(11):2525-2530. Pubmedid: 23839018. Pmcid: PMC3810840.
  • Gray JE, Altiok S, Alexandrow MG, Walsh FW, Chen J, Schell MJ, Tai DF, Bepler G. Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokers. Cancer. 2013 Mar;119(5):1023-1032. Pubmedid: 23065656. Pmcid: PMC3578040.
  • Bepler G, Williams C, Schell MJ, Chen W, Zheng Z, Simon G, Gadgeel S, Zhao X, Schreiber F, Brahmer J, Chiappori A, Tanvetyanon T, Pinder-Schenck M, Gray J, Haura E, Antonia S, Fischer JR. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2013 Jul;31(19):2404-2412. Pubmedid: 23690416. Pmcid: PMC3691357.
  • Hall RD, Gray JE, Chiappori AA. Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer. Cancer Control. 2013 Jan;20(1):22-31. Pubmedid: 23302904.
  • Alexandrow MG, Song LJ, Altiok S, Gray J, Haura EB, Kumar NB. Curcumin: a novel Stat3 pathway inhibitor for chemoprevention of lung cancer. Eur J Cancer Prev. 2012 Sep;21(5):407-412. Pubmedid: 22156994. Pmcid: PMC3319490.
  • Gray J, Cubitt CL, Zhang S, Chiappori A. Combination of HDAC and topoisomerase inhibitors in small cell lung cancer. Cancer Biol Ther. 2012 Jun;13(8):614-622. Pubmedid: 22441819. Pmcid: PMC3408970.
  • Jacobsen PB, Wells KJ, Meade CD, Quinn GP, Lee JH, Fulp WJ, Gray JE, Baz RC, Springett GM, Levine RM, Markham MJ, Schreiber FJ, Cartwright TH, Burke JM, Siegel RD, Malafa MP, Sullivan D. Effects of a brief multimedia psychoeducational intervention on the attitudes and interest of patients with cancer regarding clinical trial participation: a multicenter randomized controlled trial. J Clin Oncol. 2012 Jul;30(20):2516-2521. Pubmedid: 22614993. Pmcid: PMC4577714.
  • Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, Sayer R, Cragun J, Clarke J, Whitaker RS, Li L, Gray J, Marks J, Ginsburg GS, Potti A, West M, Nevins JR, Lancaster JM. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol. 2012 Feb;30(6):678. Pubmedid: 22451975.
  • Gray JE, Laronga C, Siegel EM, Lee JH, Fulp WJ, Fletcher M, Schreiber F, Brown R, Levine R, Cartwright T, Abesada-Terk G, Kim G, Alemany C, Faig D, Sharp P, Markham MJ, Shibata D, Malafa M, Jacobsen PB. Degree of variability in performance on breast cancer quality indicators: findings from the Florida initiative for quality cancer care. J Oncol Pract. 2011 Jul;7(4):247-251. Pubmedid: 22043190. Pmcid: PMC3140448.
  • Gray J, Chiappori A. Targeted cancer therapy: dendritic cell metabolism. Ther Deliv. 2011 Feb;2(2):133-136. Pubmedid: 22833938.
  • Sequist LV, Gettinger S, Senzer NN, Martins RG, Jänne PA, Lilenbaum R, Gray JE, Iafrate AJ, Katayama R, Hafeez N, Sweeney J, Walker JR, Fritz C, Ross RW, Grayzel D, Engelman JA, Borger DR, Paez G, Natale R. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol. 2010 Nov;28(33):4953-4960. Pubmedid: 20940188. Pmcid: PMC4676802.
  • Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, Gray J, Litschauer S, Tetteh L, Neuger A, Song L, Rawal B, Schell MJ, Bepler G. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol. 2010 Mar;28(8):1387-1394. Pubmedid: 20142592. Pmcid: PMC3040065.
  • Lee MC, Gray J, Han HS, Plosker S. Fertility and reproductive considerations in premenopausal patients with breast cancer. Cancer Control. 2010 Jul;17(3):162-172. Pubmedid: 20664513.
  • Gray J, Sommers E, Alvelo-Rivera M, Robinson L, Bepler G. Neoadjuvant chemotherapy for resectable non-small-cell lung cancer. Oncology (Williston Park). 2009 Sep;23(10):879-886. Pubmedid: 19839429.
  • Gray J, Mao J, Szabo E, Kelley M, Kurie J, Bepler G. Lung cancer chemoprevention: ACCP evidence-based clinical practice guidelines (2nd Edition). Chest. 2007 Sep;132(3 Suppl):56S-68S. Pubmedid: 17873160.
  • Gray J, Alberts W, Bepler G. Statins and lung cancer risk. Chest. 2007 May;131(5):1274-1275. Pubmedid: 17494775.
  • Gray J, Murren J, Sharma A, Kelley S, Detterbeck F, Bepler G. Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab. J Thorac Oncol. 2007 Jun;2(6):571-573. Pubmedid: 17545855.
  • Nanjundan M, Nakayama Y, Cheng KW, Lahad J, Liu J, Lu K, Kuo WL, Smith-McCune K, Fishman D, Gray JW, Mills GB. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer Res. 2007 Apr;67(7):3074-3084. Pubmedid: 17409414.
  • Lancaster J, Carney M, Gray J, Myring J, Gumbs C, Sampson J, Wheeler D, France E, Wiseman R, Harper P, Futreal P. BRCA1 and BRCA2 in breast cancer families from Wales: moderate mutation frequency and two recurrent mutations in BRCA1. Br J Cancer. 1998 Dec;78(11):1417-1420. Pubmedid: 9836472 .